The pharmaceutical name for Apcalis is Tadalafil, and it relates to the PDE-5 family of vasodilators. These drugs operate by expanding the blood capillaries in the body; especially around the genital area. It then, allows stronger blood flow to enable an erection. Apcalis is not an aphrodisiac and without sexual frenzy, no erection can be achievable.
Discount Coupon : 10% Cash Back on Order $100
- Product Code: Apcalis sx
- Availability: In Stock
Delivery Time : Average (7-12 Working Days)
|Product||Dosage||Pack Size||Free Pills||Price||Quantity||Order|
|Apcalis sx||20mg||30 Pills||$99.00||
|Apcalis sx||20mg||60 Pills||$149.00||
What are the Apcalis prescribed doses?
20mg is the administrable dose. It is administrable 25 minutes before getting involved in any sexual activity. They kick in within 45 minutes after consumption and last 4-6 hours.
What are the additional outcomes one has to deal with while using Apcalis medication?
- Flushing on the face
- increased tiredness
- blurry vision
- Nostril blockage etc.
These are some of the ordinarily encountered side effects.
What are the precautions one must be aware while dealing with Apcalis?
Apcalis Tablet is proven to be suitable for the majority while leaving behind some. Patients under treatment with the following conditions; or any ongoing managed disease, should consult their Doctor before taking Apcalis Tablet.
- Heart Linked & Cardiovascular diseases comprising aortic stenosis, idiopathic hypertrophic subaortic stenosis, and general ventricular outflow obstruction.
- Stroke, myocardial infarction (heart attack) or severe arrhythmia.
- Cardiac failure or coronary artery disease producing unstable angina.
- Blood Pressure related diseases including Hypertension & Hypotension and patients with severely impaired autonomic control of blood pressure.
- Resting hypotension (low blood pressure) of (BP <90/50)
- Resting hypertension (high blood pressure) of (BP >170/110)
- Retinitis pigmentosa (genetic disease of the retina)
- Sickle cell or other related anemias
- HIV (specifically on treatment with protease inhibitors)
- Organ donor recipients